COVID-19 Vaccine Commercialization Will Be Costly for U.S. Health System

COVID-19 vaccines could add billions of dollars to overall health care spending each year if the federal government’s purchasing program ends early next year, according to a Kaiser Family Foundation analysis. To date, the federal government has spent about $25 billion on purchasing Pfizer and Moderna COVID-19 vaccines combined, at a weighted average purchase price of $20.69 per dose.

Pfizer and Moderna both announced that the average commercial price per dose for their vaccines could be three to four times greater than the price paid by the government, between $82 and $130 per dose. If half of U.S. adults receive a booster shot at the expected commercial prices, it could cost between $3.7 billion and $14.8 billion to purchase enough doses for the group (129 million).

© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

vial-with-syringe
October 27

End of Government Purchasing, PHE Could Lead to Access, Pricing Issues for COVID Treatments

READ MORE
white-house
August 25

Insurers Brace for When U.S. Stops Buying COVID-19 Vaccines, Therapeutics

READ MORE
covid-vax-bottle-machine
December 21

COVID Vaccine Prices Set to Rise After Commercialization — But Are They Fair?

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today